Healthcare · Drug Manufacturers - Specialty & Generic
Made onJul 23, 2026
Price at call$9.85
6-month call Bear -5.1%
Target by Jan 2027$9.35
Great value below$8.25
Modelv0.6.0
Projection vs Actual
(6M history + forecast)
The masterbrain's trajectory (blue, curved through its 7 checkpoints), the deterministic v0.3 control (dashed), and the actual price (green) overlaid from the prediction date forward.
Forecast Change-5.1% to $9.35
Predicted High$9.90in 2 weeks
Predicted Low$9.35at 6 months
Max Drawdown (predicted)-5.1%
Forecast
The masterbrain trajectory — 7 dated checkpoints. Short rungs (2w, 1m) show the typical range as the primary claim; point calls run from 2 months out. Every claim still gets graded.
Predicted Jul 23, 2026 3:35 am
Bear
HLN trends lower to
$9.35
(-5.1% from $9.85)
by Jan 2027.
ride-then-fade
ThesisHLN trades slightly above composite fair value with modest quality but weak value net; a defensive low-beta name in a neutral tape should drift gently toward the $9.29 deserved-value anchor, with the July 30 earnings print as the near-term swing factor.
Invalidated ifAn earnings beat with raised guidance pushing shares above $10.50, or a miss cracking $9.00, would invalidate the slow-drift thesis.
Checkpointtime after the call
Datewhen it gets graded
Predictedthe claim: closing price
Current priceactual close — fills in over time
Predicted returnpredicted vs $9.85 at call
Conv.brain's confidence, 1–10
Driverwhy the brain put the point here
Prediction made
Jul 23, 2026
—
$9.85at call
—
—
The anchor — every point below is measured from this price and date.
2 weeks
Aug 6, 2026
$9.38–$10.32typical range · internal point $9.90
—
±4.8%
5/10
Earnings print lands in window, modest volatility either way
What actually happened:
closed $9.95
on Aug 5, 2026 = +1.0% vs the call
(predicted +0.5%)
· direction HIT
(called flat, was flat)
· off by 0.5 pp
· accuracy 10/10
· typical range ±4.8%:
inside the band
· S&P +4.3%
over the same window — beat it
1 month
Aug 23, 2026
$9.17–$10.53typical range · internal point $9.75
—
±6.9%
6/10
Post-earnings drift as defensive story reasserts
What actually happened:
closed $10.00
on Aug 21, 2026 = +1.5% vs the call
(predicted -1.0%)
· direction HIT
(called flat, was flat)
· off by 2.5 pp
· accuracy 9/10
· typical range ±6.9%:
inside the band
· S&P +3.6%
over the same window — lagged it
2 months
Sep 23, 2026
$9.65
—
-2.0%
6/10
Value gravity toward $9.29 deserved value begins
3 months
Oct 23, 2026
$9.55
—
-3.0%
5/10
Neutral tape, low beta keeps drift shallow
4 months
Nov 23, 2026
$9.45
—
-4.1%
5/10
Continued mean reversion toward anchors
5 months
Dec 23, 2026
$9.40
—
-4.6%
4/10
Year-end positioning in defensive names
6 months
Jan 23, 2027
$9.35
—
-5.1%
4/10
Converges near deserved value baseline
Why ranges on the short rungs?
A 102-prediction trial (2026-07-21) showed 2-week point calls carry no information here —
three prompt formulations all lost to simply predicting zero — while the stock's own
volatility scale (σ×√t) described those windows well. So the short rungs claim what's
actually knowable: the typical travel, with earnings timing flagged where the variance
will come from. The internal point calls keep being generated and graded to map where
real skill begins. Full evidence: stocks/predictions/V0.5-DESIGN.md §8.
Deterministic control (v0.3 value line) targets
$9.74
(-1.1%)
— both lines get graded at every checkpoint, so the brain has to beat the formula, not just replace it.
Brain: claude-opus-4-7.